Novo Nordisk open to New York listing upgrade, CEO Doustdar tells FT
Novo Nordisk open to New York listing upgrade, CEO Doustdar tells FT Sept 23 (Reuters) - Novo Nordisk NOVOb.CO is open to the idea of upgrading its New York listing as part of efforts to raise the Danish weight-loss drugmaker's profile in the country, its chief executive told Financial Times in an interview published on Wednesday.
"I clearly do see some advantages with that," CEO Mike Doustdar told the newspaper when asked whether Novo would consider a direct listing on the New York Stock Exchange, replacing the American depositary receipts that currently provide U.S. investors access to the stock.
(Reporting by Rishabh Jaiswal in Bengaluru; Editing by Sherry Jacob-Phillips)
((rishabh.jaiswal@thomsonreuters.com; +91 9916719147))
Recent news on Novo Nordisk A/S
See all newsTrial failures of Novartis, Novo Nordisk heart drugs leave experts guessing
Brief: Novo Real-World Studies Link Wegovy 2.4 MG To Reductions In Liver Enzymes, Weight, Blood Sugar In Adults With Mash
Lilly to sell obesity drugs directly on Hims & Hers site (updated)
Lilly to sell obesity drugs directly on Hims & Hers site
Brief: Executive Martin Holst Lange Sold Novo Shares Worth DKK 3.4 Mln